MAP±s.e.m. measured telemetrically in KI and WT mice 1–25 min after challenge with PBS (10 ml kg−1 IV; WT: n=8, KI: n=9; a,b), L-NAME (100 mg kg−1 IV; WT: n=7, KI: n=4; a), DETA-NO (60 mg kg−1 IV; WT: n=7, KI: n=9; b), PBS (10 ml kg−1 IP; WT: n=7, KI: n=10; c), SNP (1.5 mg kg−1 IP; WT: n=5, KI: n=6; c), vehicle (10 ml kg−1 IP; WT: n=5, KI: n=9; d), BAY 41-2772 (4 mg kg−1 IP; WT: n=5, KI: n=9; d), vehicle (10 ml kg−1 IV; WT: n=7, KI: n=7; e) or cinaciguat (300 mg kg−1 IV; WT: n=8, KI: n=7; e). *P<0.05, **P<0.01 and *** P<0.001 compared with PBS or vehicle by residual maximum likelihood (REML) (see also ).